Publications by authors named "M D Mahoney"
Article Synopsis
- - Deep learning can enhance patient care in digital pathology by extracting valuable features from biomedical images using Vision Transformer (ViT) models, which are better at handling long-range spatial relationships compared to traditional convolutional networks.
- - The main challenge with ViT models is the risk of overfitting due to a lack of annotated datasets, which can result in inaccurate predictions.
- - The introduction of Training Attention and Validation Attention Consistency (TAVAC) helps evaluate and prevent overfitting by comparing attention regions in training and testing phases, and it also improves interpretative reproducibility in biomedical and other image analyses.
Purpose: We evaluated whether IDO-inhibitor BMS986205 (IDOi) + PD-1 inhibitor nivolumab enhanced T-cell activity and augmented immune-mediated antitumor responses in untreated, resectable HNSCC. We employed response-adaptive surgical timing to identify responders to immunotherapy and enhance their response.
Patients And Methods: Patients with HNSCC were 3:1 randomized to receive nivolumab with or without BMS986205 PO daily (NCT03854032).
Significance: Nicotine-containing products, labelled as being 'tobacco-free' nicotine (TFN), are marketed to consumers as alternatives to conventional tobacco products. Little is known about these emerging products and their contents.
Methods: Moisture, total nicotine and pH content were analysed in 70 commercially available TFN products, covering five different types (lozenges, chewing gum, loose leaf, toothpicks and pouches).
Outpatient parenteral antimicrobial therapy (OPAT) has become more common in infectious diseases practice settings. Similarly, OPAT-related publications have also increased. The objective of this article was to summarize clinically important OPAT-related publications from 2023.
View Article and Find Full Text PDFThe translation of pre-clinical anti-cancer therapies to regulatory approval has been promising, but slower than hoped. While innovative and effective treatments continue to achieve or seek approval, setbacks are often attributed to a lack of efficacy, failure to achieve clinical endpoints, and dose-limiting toxicities. Successful efforts have been characterized by the development of therapeutics designed to specifically deliver optimal and effective dosing to tumour cells while minimizing off-target toxicity.
View Article and Find Full Text PDF